12:00 27/03/2015 Arena Investors Need To Pay Attention To Competition
Arena Investors Need To Pay Attention To Competition
Seeking Alpha (registration) - Mar 27, 2015
If you are invested in Arena Pharmaceuticals (NASDAQ:ARNA), some news delivered today by competitor Orexigen (NASDAQ:OREX) is something that you need to consider.
Orexigen Therapeutics Embarrasses Arena and VIVUS Again (VVUS, OREX ... - SmallCap Network

20:48 24/03/2015 ARNA Crosses Below Key Moving Average Level
ARNA Crosses Below Key Moving Average Level
Nasdaq - Mar 24, 2015
In trading on Tuesday, shares of Arena Pharmaceuticals Inc (Symbol: ARNA) crossed below their 200 day moving average of $4.54, changing hands as low as $4.50 per share.

12:45 23/03/2015 Arena Pharmaceuticals Could Have Better Luck In Quarter 2 (ARNA)
Arena Pharmaceuticals Could Have Better Luck In Quarter 2 (ARNA)
Seeking Alpha (registration) - Mar 23, 2015
New prescription numbers for week ending March 13 have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The week-to-week improvements in total (TRx) and new (NRx) prescriptions are ...

21:33 17/03/2015 Arena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for ...
Arena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for ...
Equities.com - Mar 17, 2015
Arena Pharmaceuticals Inc. ($ARNA) experienced unusually high volume on Mar. 17, as the stock gained 5.27% to a closing price of $4.99.

20:15 13/03/2015 Arena Pharmaceuticals Now Likely To Miss Q1 Estimates (ARNA)
Arena Pharmaceuticals Now Likely To Miss Q1 Estimates (ARNA)
Seeking Alpha (registration) - Mar 13, 2015
New prescription numbers have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The 3.3% week-to-week improvement in total prescriptions (TRx) is a slight improvement over the previous ...
Healthcare Stocks in the Spotlight: Arena Pharmaceuticals (ARNA), Genetic ... - Techsonian (press release)

6:22 13/03/2015 Zacks Rating Update on Arena Pharmaceuticals, Inc.
Zacks Rating Update on Arena Pharmaceuticals, Inc.
Stafford Daily - Mar 13, 2015
Research firm Zacks has rated Arena Pharmaceuticals (NASDAQ:ARNA) and has ranked it at 4, indicating that for the short term the shares are a sell.

12:48 11/03/2015 Fourth quarter updates on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Fourth quarter updates on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Inside Trade - Mar 11, 2015
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. Short Interest Disclosure - Stafford Daily
Mid-Day Buzzers – Arena Pharmaceuticals (ARNA), Marvell (MRVL), Himax ... - Techsonian (press release)

18:33 04/03/2015 Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock
Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock
TheStreet.com - Mar 4, 2015
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.

23:37 02/03/2015 Arena Pharmaceuticals Misses Q4 Expectations
Arena Pharmaceuticals Misses Q4 Expectations
Benzinga - Mar 2, 2015
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported financial results Monday for the fourth quarter and full year ended December 31, 2014.
Analyst Rating Update on Arena Pharmaceuticals, Inc. - Stafford Daily
Stock To Watch : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Markets Wired

20:03 02/03/2015 Earnings Reaction History: Arena Pharmaceuticals, Inc., 42.9% Follow-Through ...
Earnings Reaction History: Arena Pharmaceuticals, Inc., 42.9% Follow-Through ...
Nasdaq - Mar 2, 2015
Over the prior three fiscal years (12 quarters), when shares of ARNA rose in the extended-hours session in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock posted additional gains in the following regular ...